Neurofibromatoses Type II – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Neurofibromatoses Type II – Drugs In Development, 2024 report and make more profitable business decisions.
Neurofibromatosis type 2 is a disorder characterized by the growth of noncancerous tumors in the nervous system. These growths develop along the nerve that carries information from the inner ear to the brain (the auditory nerve). Tumors that occur on other nerves are also commonly found with this condition. The signs and symptom are hearing loss, ringing in the ears (tinnitus), and problems with balance.
The Neurofibromatoses Type II drugs in development market research report provide comprehensive information on the therapeutics under development for Neurofibromatoses Type II, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neurofibromatoses Type II and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Neurofibromatoses Type II | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 8 molecules, with 8 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Neurofibromatoses Type II therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Neurofibromatoses Type II pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Neurofibromatoses Type II treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AstraZeneca PlcBetta Pharmaceuticals Co Ltd
Millennium Pharmaceuticals Inc
Mulberry Biotherapeutics Inc
OncoTherapy Science Inc
Plex Pharmaceuticals Inc
PRG S&Tech Inc
Recursion Pharmaceuticals Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Neurofibromatoses Type II reports